97 related articles for article (PubMed ID: 23482788)
1. Biomarkers as prognostic factors for cN2 or 3 non-small cell lung cancer treated by induction chemoradiotherapy and surgery.
Yokomise H; Liu D; Chang S; Go T; Ishikawa S; Misaki N; Nakashima N
Anticancer Res; 2013 Mar; 33(3):1107-15. PubMed ID: 23482788
[TBL] [Abstract][Full Text] [Related]
2. [Expression and predictive role of excision repair cross complementation group 1, ribonucleotide reductase subunit M1, and β-tubulin 3 in postoperative patients with non-small cell lung cancer receiving adjuvant chemotherapy].
Shi Y; Chen L; Li J; Lü YL; Jiao SC
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2010 Aug; 32(4):375-82. PubMed ID: 20868593
[TBL] [Abstract][Full Text] [Related]
3. Customized Adjuvant Chemotherapy Based on Biomarker Examination May Improve Survival of Patients Completely Resected for Non-small-cell Lung Cancer.
Liu D; Nakashima N; Nakano J; Tarumi S; Matsuura N; Nakano T; Nii K; Tokunaga Y; Go T; Yokomise H
Anticancer Res; 2017 May; 37(5):2501-2507. PubMed ID: 28476819
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy followed by surgery on the basis of biomarker examination for patients with advanced non-small cell lung cancer.
Yokomise H; Liu D; Ishikawa S; Go T; Gotoh M; Okuda M; Tarumi S; Kasai Y; Matsuura N
Anticancer Res; 2013 Dec; 33(12):5597-602. PubMed ID: 24324104
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of ERCC1, RRM1 and BRCA1 in surgically-treated patients with non-small cell lung cancer.
Pesta M; Kulda V; Fiala O; Safranek J; Topolcan O; Krakorova G; Cerny R; Pesek M
Anticancer Res; 2012 Nov; 32(11):5003-10. PubMed ID: 23155271
[TBL] [Abstract][Full Text] [Related]
6. Expression of ERCC1, TYMS, RRM1, TUBB3, non-muscle myosin II, myoglobin and MyoD1 in lung adenocarcinoma pleural effusions predicts survival in patients receiving platinum-based chemotherapy.
Jiang H; Wang H; Wang S; Pei Z; Fu Z; Fang C; Wang J; Lu Q; Wang E; Li J
Mol Med Rep; 2015 May; 11(5):3523-32. PubMed ID: 25573098
[TBL] [Abstract][Full Text] [Related]
7. Combined analysis of mRNA expression of ERCC1, BAG-1, BRCA1, RRM1 and TUBB3 to predict prognosis in patients with non-small cell lung cancer who received adjuvant chemotherapy.
Leng XF; Chen MW; Xian L; Dai L; Ma GY; Li MH
J Exp Clin Cancer Res; 2012 Mar; 31(1):25. PubMed ID: 22439756
[TBL] [Abstract][Full Text] [Related]
8. ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer.
Su C; Zhou S; Zhang L; Ren S; Xu J; Zhang J; Lv M; Zhang J; Zhou C
Med Oncol; 2011 Dec; 28(4):1411-7. PubMed ID: 20467918
[TBL] [Abstract][Full Text] [Related]
9. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H
Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
[TBL] [Abstract][Full Text] [Related]
10. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation.
Azuma K; Sasada T; Kawahara A; Hattori S; Kinoshita T; Takamori S; Ichiki M; Imamura Y; Ikeda J; Kage M; Kuwano M; Aizawa H
Cancer Chemother Pharmacol; 2009 Aug; 64(3):565-73. PubMed ID: 19123003
[TBL] [Abstract][Full Text] [Related]
11. The prognostic significance of ERCC1, BRCA1, XRCC1, and betaIII-tubulin expression in patients with non-small cell lung cancer treated by platinum- and taxane-based neoadjuvant chemotherapy and surgical resection.
Kang CH; Jang BG; Kim DW; Chung DH; Kim YT; Jheon S; Sung SW; Kim JH
Lung Cancer; 2010 Jun; 68(3):478-83. PubMed ID: 19683826
[TBL] [Abstract][Full Text] [Related]
12. mRNA expression and clinical significance of ERCC1, BRCA1, RRM1, TYMS and TUBB3 in postoperative patients with non-small cell lung cancer.
Han Y; Wang XB; Xiao N; Liu ZD
Asian Pac J Cancer Prev; 2013; 14(5):2987-90. PubMed ID: 23803067
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of ERCC1, RRM1, BRCA1 and SETDB1 in early stage of non-small cell lung cancer.
Lafuente-Sanchis A; Zúñiga Á; Galbis JM; Cremades A; Estors M; Martínez-Hernández NJ; Carretero J
Clin Transl Oncol; 2016 Aug; 18(8):798-804. PubMed ID: 26542178
[TBL] [Abstract][Full Text] [Related]
14. Multiplex real-time PCR for RRM1, XRCC1, TUBB3 and TS mRNA for prediction of response of non-small cell lung cancer to chemoradiotherapy.
Wu GQ; Liu NN; Xue XL; Cai LT; Zhang C; Qu QR; Yan XJ
Asian Pac J Cancer Prev; 2014; 15(10):4153-8. PubMed ID: 24935362
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of the mRNA expression of
Sun S; Shi W; Wu Z; Zhang G; Yang BO; Jiao S
Exp Ther Med; 2015 Sep; 10(3):937-941. PubMed ID: 26622418
[TBL] [Abstract][Full Text] [Related]
16. Expression of ERCC1 and class III β-tubulin is associated with the survival of resected stage III non-small cell lung cancer patients treated with induction chemoradiotherapy using carboplatin-taxane.
Huang CL; Kadota K; Liu D; Ueno M; Nakasima N; Ishikawa S; Gotoh M; Misaki N; Chang SS; Yokomise H
Exp Ther Med; 2010 May; 1(3):445-451. PubMed ID: 22993560
[TBL] [Abstract][Full Text] [Related]
17. Extensive analysis of the molecular biomarkers excision repair cross complementing 1, ribonucleotide reductase M1, β-tubulin III, thymidylate synthetase, and topoisomerase IIα in breast cancer: Association with clinicopathological characteristics.
Li J; Sun P; Huang T; He S; Li L; Xue G
Medicine (Baltimore); 2021 Apr; 100(14):e25344. PubMed ID: 33832110
[TBL] [Abstract][Full Text] [Related]
18. Gene expression profiles of ERCC1, TYMS, RRM1, TUBB3 and EGFR in tumor tissue from non-small cell lung cancer patients.
Yu D; Li J; Han Y; Liu S; Xiao N; Li Y; Sun X; Liu Z
Chin Med J (Engl); 2014; 127(8):1464-8. PubMed ID: 24762590
[TBL] [Abstract][Full Text] [Related]
19. [ERCC1 expression as a predictor of survival after operation in stage I non-small cell lung cancer patients].
Ding Z; Zhang J; Shao J
Zhongguo Fei Ai Za Zhi; 2010 May; 13(5):522-5. PubMed ID: 20677653
[TBL] [Abstract][Full Text] [Related]
20. Induction chemoradiotherapy (carboplatin-taxane and concurrent 50-Gy radiation) for bulky cN2, N3 non-small cell lung cancer.
Yokomise H; Gotoh M; Okamoto T; Yamamoto Y; Ishikawa S; Nakashima T; Masuya D; Liu D; Huang CL
J Thorac Cardiovasc Surg; 2007 May; 133(5):1179-85. PubMed ID: 17467426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
